Flagship Harbor Advisors’s Arbutus Biopharma ABUS Stock Holding History

Flagship Harbor Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200	Closed	-$962	–	739
2025 Q4	$962	Buy	+200	New	+$899	﹤0.01%	1943
2020 Q4	–	Sell	-200	Closed	–	–	568
2020 Q3	$0	Hold	200	–	–	﹤0.01%	1895
2020 Q2	$0	Hold	200	–	–	﹤0.01%	1998
2020 Q1	$0	Hold	200	–	–	﹤0.01%	1856
2019 Q4	$1K	Hold	200	–	–	﹤0.01%	1777
2019 Q3	$0	Hold	200	–	–	﹤0.01%	1821
2019 Q2	$0	Hold	200	–	–	﹤0.01%	1844
2019 Q1	$0	Hold	200	–	–	﹤0.01%	1825
2018 Q4	$0	Hold	200	–	–	﹤0.01%	1815
2018 Q3	$2K	Hold	200	–	–	﹤0.01%	1877
2018 Q2	$1K	Buy	+200	New	+$1.19K	﹤0.01%	1910

Other funds holding ABUS

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Flagship Harbor Advisors's ABUS Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Arbutus Biopharma (ABUS) in Q1 2026, closing a stake of 200 shares — an estimated $962 sold.

Flagship Harbor Advisors first reported a position in ABUS in Q2 2018 and held it in 11 quarters. The position peaked at $2K in Q3 2018. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Flagship Harbor Advisors reported no remaining Arbutus Biopharma position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 200 Arbutus Biopharma shares in Q1 2026, an estimated $962.
Flagship Harbor Advisors first reported a position in Arbutus Biopharma in Q2 2018 and held it in 11 quarters.
Flagship Harbor Advisors's Arbutus Biopharma position peaked at $2K in Q3 2018.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.